200 participants
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
- Study Type:
- OBSERVATIONAL
- Last Updated:
- 2026-08-31
- Start Date:
- 2026-01-29
- Completion:
- 2027-11-01
Conditions
- Inflammatory Bowel Disease (IBD)
- Crohn Disease (CD)
- Ulcerative Colitis (UC)
- IBD-unclassified (IBD-U)
Interventions
- BIOLOGICAL
No Results Yet